Cybersecurity

Improving immune function: Rapamycin clinical trial launched

25 sec read4 views0 listens

Researchers at the University of Arizona's R. Ken Coit College of Pharmacy are launching a Phase 3 clinical trial to assess whether rapamycin, an immunosuppressant drug, can improve immune function and resilience in older adults. This study is significant as it explores potential anti-aging benefits and could lead to new approaches for enhancing healthspan in the aging population.

Read the full article at Digital Journal

Want to create content about this topic? Use Nemati AI tools to generate articles, social posts, and more.

Former FDA leaders, pharma speak out on mifepristone

The Supreme Court's decision on mifepristone could redefine FDA regulatory authority over abortion medications. This impacts tech professionals developing health apps and services related to reproductive health, as it may alter how digital health sol...

Ali Nemati

Biotech & Pharma5 days ago25 sec read

STAT+: The biotech news you need to read today

Capricor Therapeutics is suing its Japanese partner, Nippon Shinyaku and NS Pharma, for mishandling the launch preparations of their Duchenne muscular dystrophy cell therapy. This legal battle highlights risks in biotech partnerships and could affect...

Ali Nemati

Health & Medicine5 days ago26 sec read

Why we left the FDA: Six former officials share their stories

Former FDA officials, including key figures like Richard Pazdur and Sheryl Lard-Whiteford, have shared their experiences and reasons for leaving during the second Trump administration. This provides critical insights into the agency's challenges and ...

Ali Nemati

Legal & Policy6 days ago28 sec read

Louisiana urges Supreme Court to leave in place order barring mailing of abortion pill

Louisiana has urged the Supreme Court to maintain a ban on mailing mifepristone, arguing it undermines abortion restrictions and causes illegal abortions in the state. This legal battle impacts tech companies involved in telehealth and pharmaceutical...

Ali Nemati

Health & Medicine6 days ago27 sec read

STAT+: Pharmalittle: We're reading about Sanofi and an FDA voucher, FDA rethinking a rejection, and more

Sanofi requested the FDA withdraw its type 1 diabetes drug, teplizumab, from a new expedited review program after disagreement over its approval. This highlights the tension between political influence and scientific decision-making in drug approvals...

Ali Nemati

Improving immune function: Rapamycin clinical trial launched

Related Articles

Former FDA leaders, pharma speak out on mifepristone

STAT+: The biotech news you need to read today

Why we left the FDA: Six former officials share their stories

Louisiana urges Supreme Court to leave in place order barring mailing of abortion pill

STAT+: Pharmalittle: We're reading about Sanofi and an FDA voucher, FDA rethinking a rejection, and more